companies developing glp 1 drugs Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Weight Loss Drugs in the
Description
When one drug inhibits CYP enzymes responsible for metabolising another CNS drug, plasma and brain concentrations may rise, increasing the risk of toxicity
More research is needed here around structured lifestyle programs to mitigate weight regain, including the addition of meal replacements
Gallbladder disease Tirzepatide has been associated with an increased risk of gallbladder disease
Once your blood sugar is stable and controlled, testing might happen every 6 months instead
Additionally, insurance coverage continues to lag behind clinical evidence, particularly for cardiovascular indications in non-diabetic patients
The index date for this group corresponded to the initial date of their obesity diagnosis
